Citigroup started coverage on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a research note published on Monday, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $21.00 price target on the stock.
Several other equities analysts have also issued reports on the stock. Guggenheim initiated coverage on shares of Mirum Pharmaceuticals in a report on Monday. They set a buy rating and a $18.00 price objective on the stock. Evercore ISI initiated coverage on shares of Mirum Pharmaceuticals in a report on Monday. They set an outperform rating and a $25.00 price objective on the stock. Five analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and a consensus target price of $25.00.
Shares of MIRM stock opened at $13.45 on Monday. Mirum Pharmaceuticals has a 52-week low of $12.05 and a 52-week high of $15.50.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).
Recommended Story: What is Blockchain?
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.